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An enhanced requirement for nutrients is a hallmark property of cancer cells. Here, we optimized an in 
vivo genetic screening strategy in acute myeloid leukemia (AML), which led to the identification of the 
myo-inositol transporter SLC5A3 as a dependency in this disease. We demonstrate that SLC5A3 is 
essential to support a myo-inositol auxotrophy in AML. The commonality among SLC5A3-dependent 
AML lines is the transcriptional silencing of ISYNA1, which encodes the rate limiting enzyme for myo-
inositol biosynthesis, inositol-3-phosphate synthase 1. We use gain- and loss-of-function experiments 
to reveal a synthetic lethal genetic interaction between ISYNA1 and SLC5A3 in AML, which function 
redundantly to sustain intracellular myo-inositol. Transcriptional silencing and DNA hyper-
methylation of ISYNA1 occur in a recurrent manner in human AML patient samples, in association 
with IDH1/IDH2 and CEBPA mutations. Our findings reveal myo-inositol as a nutrient dependency in 
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Statement of significance  
We show how epigenetic silencing can provoke a nutrient dependency in AML by exploiting a 
synthetic lethality relationship between biosynthesis and transport of myo-inositol. Blocking the 
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Introduction 
A consistent property of cancer cells is metabolic dysfunction, which can occur to support the 
energetic and biosynthetic requirements of a rapidly growing tumor (1). One manifestation of this 
process is that tumor cells become more dependent on extracellular nutrient uptake for their growth 
and viability than normal tissues, a process referred to as auxotrophy (2). In many tumors, 
auxotrophies are driven by an elevated anabolic demand for metabolite building blocks, as is the case 
for serine (3), glutamine (4), and cysteine (5). However, cancer cells can also develop nutrient 
dependencies through an acquired defect in de novo metabolite biosynthesis pathways. One of the 
clearest examples of this is the dependence of lymphoid cancers on extracellular asparagine, which 
occurs because the rate limiting enzyme in asparagine biosynthesis becomes epigenetically silenced in 
this malignancy (6). This nutrient dependency can be exploited by infusion of recombinant 
asparaginase, which is an approved chemotherapeutic in acute lymphoblastic leukemia that depletes 
asparagine from the plasma (7). Arginine and cholesterol auxotrophies in cancer have also been 
attributed to diminished expression of key biosynthetic enzymes (8, 9). While these examples point to 
the therapeutic significance of auxotrophy in human cancer, few systematic surveys of nutrient 
dependencies have been performed in cancer to date.  
 
Solute carriers (SLCs) are an important class of transporter proteins that regulate nutrient utilization in 
normal and neoplastic contexts. The human genome encodes over 400 SLC proteins organized into 65 
subfamilies, which regulate intracellular levels of amino acids, sugars, ions, lipids, neurotransmitters, 
and drugs (10). SLCs contain transmembrane alpha helices that form a substrate binding channel, 
which often use ion gradients to co-transport substrates into cells (11). Owing to their specificity for 
transporting specific substrates, genetic targeting of SLCs provides a powerful tool for manipulation of 
intracellular metabolite levels and for exploration of nutrient dependencies (12, 13). Numerous SLC 
genes are mutated in human genetic disorders and an emerging body of evidence suggests a role for 
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SLC proteins in the pathogenesis of human cancer (14, 15, 16). Moreover, the substrate binding cavity 
of SLC proteins can be blocked with small molecules, which has fueled an interest in this class of 
proteins as drug targets (16, 17, 18).  
 
Myo-inositol is an abundant carbocyclic sugar alcohol in eukaryotic cells (19, 20). One of the most 
well-characterized functions of myo-inositol is as a head group component of lipid 
phosphatidylinositols (PIs), which are important signaling molecules that function downstream of 
growth factor signaling. In this lipid context, the phosphorylation state of myo-inositol is highly 
regulated by kinases (e.g. PI3K) and phosphatases (e.g. PTEN) to control the AKT-mTOR signaling 
axis (21). In addition, phospholipase C can release inositol triphosphates from PIs, which function as a 
second messenger that promotes the intracellular release of calcium from the endoplasmic reticulum 
(22, 23). Myo-inositol is also an osmolyte, whose intracellular concentrations can be regulated to allow 
cells to survive in hypertonic environments (24, 25).  
 
Intracellular myo-inositol can be derived from three different sources: (1) de novo biosynthesis from 
glucose (26, 27); (2) regeneration from inositol phosphates via the action of phosphatases (28); or (3) 
uptake from the extracellular environment by inositol transporters (29). For de novo biosynthesis, 
glucose is first phosphorylated by hexokinase and then converted to myo-inositol-1-phosphate by the 
enzyme inositol-3-phosphate synthase 1 (ISYNA1), and finally dephosphorylated by inositol 
monophosphatase to form free myo-inositol. Importantly, ISYNA1 catalyzes the rate-limiting step in 
myo-inositol biosynthesis (30). For extracellular uptake, there are three known myo-inositol SLC 
transporters in human, SLC5A3 (31), SLC5A11 (32), and SLC2A13 (33). Both SLC5A3 and 
SLC5A11 are sodium ion coupled inositol transporters, whereas SLC2A13 is a proton-coupled inositol 
transporter (29). Among these transporters, SLC5A3 is the most widely expressed across different 
tissues and has the highest affinity for myo-inositol (33, 34, 35, 36, 37).  
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In this study, we set out to identify genetic dependencies needed for the growth of acute myeloid 
leukemia cells in vivo. This approach identified the myo-inositol transporter SLC5A3 as an in vivo-
relevant dependency unique to AML. We show that this dependency is caused by aberrant silencing of 
ISYNA1. While loss of ISYNA1 has no detectable effect on the fitness of AML cells, it causes an 
enhanced dependency on SLC5A3 and on extracellular myo-inositol for cell viability. Taken together, 
our findings reveal myo-inositol auxotrophy as metabolic vulnerability in AML.  
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Results 
A domain-focused CRISPR screening method for identifying in vivo-relevant AML dependencies 
The genetic dependencies of a cancer cell can be markedly altered by in vitro versus in vivo growth 
conditions (38), particularly the requirement for cell surface receptors and metabolic enzymes whose 
function is influenced by the extracellular microenvironment. This issue motivated us to develop a 
robust screening method for interrogating genetic dependencies of human AML cells grown in vivo. 
For this study, we employed our previously cloned domain-focused sgRNA libraries targeting 
transcription factors (39), chromatin regulators (40, 41), and kinases (42). In addition, we cloned 
domain-focused sgRNA libraries targeting G-protein coupled receptors, ion channels, solute carriers, 
glycosyltransferases, proteases, and membrane proteins, which were all cloned into the LRG2.1T 
vector backbone which contains an optimized sgRNA2.1 scaffold (43). Our screens were performed by 
lentiviral transduction of each sgRNA library into the AML cell line MOLM-13, engineered to express 
Cas9 and firefly luciferase. A key optimization step was to select for high engraftment efficiency of 
this MOLM-13 line through pre-transplantation before running the pooled screen (Figure 1A). After 
transduction with an sgRNA library, MOLM-13 cells were injected via tail vein into 10-20 immune-
deficient mice. MOLM-13 cells were allowed to expand for 12 days in vivo, followed by the mice 
being sacrificed and genomic DNA being isolated from bone marrow and spleen tissue for deep 
sequencing of the PCR-amplified sgRNA cassette (Figure 1A). While establishing this procedure, we 
found that pooling of bone marrow or spleen samples prior to PCR maximized sgRNA representation 
and the overall accuracy of the screens. Importantly, the sgRNA read count distribution (a reflection of 
screen quality) and the depletion pattern of control sgRNAs of in vivo samples was comparable to the 
same screen being performed in vitro (Figure S1, Supplementary Table 1). We have previously 
characterized AML dependencies in vitro using sgRNA libraries targeting kinases (42), transcription 
factors (39), and chromatin regulators (40, 41). The in vivo CRISPR screening showed highly 
consistent results with our previous findings (Figure 1B-D). In addition, the in vivo screen results 
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between pooled spleen and bone marrow samples were consistent as well (Figure S2). The overall 
accuracy of our screen was further supported by the in vivo-specific depletion of sgRNAs targeting 
CD47 (44, 45, 46) and CXCR4 (47), which are known AML dependencies that regulate interactions 
with the in vivo microenvironment (Figure 1E). In contrast to previous in vivo RNAi screening in 
leukemia that shows only ~10% of in vivo dependencies overlapping with in vitro targets (48), our 
screening showed largely consistent results between in vivo and in vitro conditions (Figure 1F, Figure 
S3, and Supplementary Table 1). From this screening effort targeting a total of 5,768 genes, we 
identified 239 targets as in vivo-relevant dependencies (Figure 1F, Supplementary Table 1).  
 
SLC5A3 dependency is in vivo-relevant and AML-specific 
While our original intent was to identify in vivo-specific dependencies, the scarcity of such hits in our 
screen prompted us to explore instead whether any in vivo-validated dependencies were unique to 
AML relative to other cancers. For this purpose, we turned to Project Achilles/DepMap, which has 
performed genome-wide CRISPR screens for essential genes in >769 diverse cancer cell lines grown in 
vitro (49, 50). Through analysis of these data, we nominated myeloid lineage TFs (MYB, CBFB, and 
SPI1) and the myo-inositol transporter protein SLC5A3 as the top leukemia-biased dependencies 
among the pool of in vivo-validated targets (Figure 2A). The AML specificity of SLC5A3 was distinct 
from other essential SLC genes, which tended to be needed across diverse cancer types (Figure 2B). 
The in vivo screening in MOLM-13 cells and our own in vitro SLC screening in 10 diverse cancer cell 
lines corroborated SLC5A3 as a unique AML dependency under in vitro and in vivo conditions (Figure 
2C, Figure S4A-E). Unlike the aforementioned myeloid TFs, no prior study has investigated the role 
for SLC5A3 in AML, which motivated our subsequent evaluation of this target. 
 
 
Validation of SLC5A3 dependency in a subset of AML cell lines 
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To validate SLC5A3 as a dependency in AML, we performed competition-based proliferation assays 
following lentiviral transduction with sgRNA-expressing vectors in Cas9-expressing AML cell lines. 
The genome editing efficiency of these sgRNAs targeting SLC5A3 was validated using genomic DNA 
qPCR with primers that hybridize to the Cas9 target sequence (Figure S5A). Using this approach, we 
validated that the cell fitness of several AML lines was impaired by SLC5A3 sgRNAs (e.g. MOLM-13, 
SEM, MV4-11, U937, EOL1), whereas other AML lines were SLC5A3 independent (e.g. HEL, 
KASUMI, SET-2) (Figure 3A, Figure S5B-C). As a control, an sgRNA targeting the DNA replication 
protein PCNA suppressed the growth of all cancer cell lines tested (Figure 3A, Figure S5B). cDNA 
rescue experiments also supported that these cell fitness alterations were due to a requirement for the 
SLC5A3 gene product and rule out off target effects as contributing to this phenotype (Figure S6A-E). 
In MOLM-13 cells, loss of SLC5A3 led to cell cycle arrest (Figure S7A-B). We also verified that 
knockout of SLC5A3 suppressed the growth of MOLM-13 cells under in vivo conditions (Figure 3B-E, 
Figure S8A-F). Collectively, these findings demonstrate that SLC5A3 is essential in a subset of AML 
cell lines under in vitro and in vivo conditions.   
 
SLC5A3-dependent AML lines are myo-inositol auxotrophs 
Since the primary substrate for SLC5A3 is myo-inositol (29), we performed liquid chromatography 
mass spectrometry (LC-MS) to measure intracellular myo-inositol levels in cancer cell lines following 
SLC5A3 inactivation. As expected, knockout of SLC5A3 in MOLM-13 or MV4-11 cells led to a 
significant reduction of intracellular myo-inositol, whereas the level of other metabolites (e.g. 
glutamine) was unaffected (Figure 4A). This finding prompted us to evaluate the impact of removing 
myo-inositol from the media of AML cell lines. Remarkably, SLC5A3-dependent cell lines MOLM-13, 
MV4-11, and U937 slowed their growth following myo-inositol depletion, whereas the growth of 
SLC5A3-independent lines HEL, SET-2, and K562 was unaffected by myo-inositol depletion (Figure 
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4B-C). Taken together, these experiments suggest that SLC5A3 dependency is associated with a myo-
inositol auxotrophy in AML.  
 
It has been shown that developmental abnormalities in Slc5a3
-/- 
mice can be rescued by providing 
supra-physiological concentrations myo-inositol in the diet, which can be transported into cells in a 
SLC5A3-independent manner via low affinity transporters (51, 52, 53). This observation motivated us 
to perform analogous experiments in SLC5A3-dependent AML cell lines by supplementing normal 
growth media with additional myo-inositol. This revealed that a ~5-fold increase in myo-inositol 
concentrations in regular growth media (RPMI) was sufficient to bypass the necessity of SLC5A3 in 
MOLM-13 and MV4-11 cell line contexts (Figure 4D). These findings lend strong support that the 
essential function of SLC5A3 in AML is the transport of extracellular myo-inositol into the cell 
interior.  
 
Transcriptional silencing of ISYNA1 leads to SLC5A3 dependency through a synthetic lethal 
genetic interaction  
We next investigated the mechanism underlying SLC5A3 dependency and myo-inositol auxotrophy in 
AML. Importantly, SLC5A3 dependency did not correlate with expression of SLC5A3, nor did it 
correlate with silencing of the alternative myo-inositol transporters SLC5A11 and SLC2A13 (Figure 
S9A-C). Furthermore, triple knockout experiments targeting SLC5A3, SLC5A11, and SLC2A13, 
failed to reveal evidence of redundancy (Figure S10A-B). These results led us to consider whether the 
myo-inositol auxotrophy in AML was due instead to an acquired defect in de novo myo-inositol 
biosynthesis (Figure 5A). By analyzing the mRNA levels of known myo-inositol biosynthesis genes, 
we noticed a significant inverse correlation between SLC5A3 dependency and expression of ISYNA1, 
which encodes the rate-limiting enzyme in myo-inositol biosynthesis (30) (Figure 5B). We confirmed 
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the heterogeneous expression of ISYNA1 in AML cell lines using western blotting, which mirrored the 
heterogeneity of mRNA levels (Figure 5C, Figure S11A).  
 
The findings above led us to hypothesize that a genetic redundancy may exist between ISYNA1 and 
SLC5A3, which represent two independent strategies for maintaining intracellular myo-inositol levels. 
To evaluate this possibility, we targeted ISYNA1 and SLC5A3 (alone and in combination) in HEL and 
K562, which are leukemia lines that express both genes. Competition-based proliferation assays using 
bi-cistronic sgRNA vectors demonstrated that dual targeting of ISYNA1 and SLC5A3 led to a more 
severe proliferation defect than the loss of each gene individually (Figure 5D-E, Figure S11B). LC-MS 
analysis demonstrated that a combined deficiency of ISYNA1 and SLC5A3 also led a more severe 
decrease in intracellular myo-inositol than observed following either single gene knockout (Figure 
S11C). Knockout of ISYNA1 in HEL cells also led to a significant reduction of intracellular myo-
inositol when cultured in myo-inositol deficient media (Figure S11D). In addition, knockout of 
ISYNA1 was sufficient to convert HEL and K562 cells into myo-inositol auxotrophs (Figure 5F-G). 
Taken together, these experiments validate a genetic redundancy between ISYNA1 and SLC5A3 to 
sustain intracellular myo-inositol and cell viability. 
 
To validate that ISYNA1 silencing is the underlying cause of myo-inositol auxotrophy and SLC5A3 
dependency in AML, we lentivirally expressed a ISYNA1 cDNA in AML cell lines that lacked 
endogenous ISYNA1 expression (MOLM-13, MV4-11, EOL1, and U937) (Figure 6A). Remarkably, 
restoring ISYNA1 was sufficient to elevate myo-inositol levels and bypass the essentiality of SLC5A3 
when cultured in normal growth media (Figure 6B-C, Figure S12). This finding was further 
corroborated using a genome-wide screening approach, which revealed SLC5A3 as the sole genetic 
dependency rescued by ISYNA1 cDNA expression (Figure S13A-E).  Furthermore, forced ISYNA1 
expression also eliminated the myo-inositol auxotrophy (Figure 6D).  
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To validate that ISYNA1 is the key enzyme for de novo myo-inositol biosynthesis from glucose, we 
performed stable isotope tracing experiment by treating the cells with 
13
C labeled glucose for 48 hours 
and measuring intracellular 
13
C labeled myo-inositol by LC-MS (Figure S14A). In MOLM-13 cells, 
the labeled glucose was only converted into myo-inositol when ISYNA1 was overexpressed (Figure 
S14B). On the contrary, a significant reduction of intracellular 
13
C labeled myo-inositol was observed 
in HEL cells following ISYNA1 knockout (Figure S14C).  
 
Aberrant ISYNA1 promoter hyper-methylation occurs recurrently in human AML patient 
samples 
We next evaluated whether epigenetic silencing of ISYNA1 occurs in human AML patient samples. In 
the cell line AML models, we noticed that transcriptional silencing of ISYNA1 was associated with 
DNA hypermethylation and the loss of histone acetylation in the vicinity of its CpG island/promoter 
(Figure S15A-B). Using Nanopore sequencing, we confirmed DNA hypermethylation at the ISYNA1 
gene in MOLM-13 and MV4-11 lines, and hypomethylation in the HEL line (Figure 7A, Figure S15C). 
Notably, these regions remained unmethylated in normal human hematopoietic stem and progenitor 
cells (HSPC) (54) (Figure 7A). Having established hypermethylation as a biomarker of ISYNA1 
silencing, we next evaluated whether this genomic region was hypermethylated in human AML patient 
samples analyzed by The Cancer Genomic Atlas (TCGA), in which 170 genetically annotated samples 
were evaluated using Illumina Infinium 450k DNA methylation assay (55).  In this study, we found 
that ISYNA1 hypermethylation was present in ~20% of human AML samples (z score>0.5), whereas 
other flanking regions lacked heterogeneity in methylation (Figure 7B, Figure S15D-E). Importantly, 
the presence of hypermethylation correlated with lower ISYNA1 expression (Figure 7C, Figure S15F). 
In addition, we found that ISYNA1 hypermethylation was significantly enriched for patients that 
possess IDH1/IDH2 or CEBPA mutations (Figure 7B, D). The TCGA AML patient gene expression 
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data further shows patients with IDH2 mutations have significantly lower ISYNA1 gene expression 
(Figure 7E). We further evaluated ISYNA1 methylation in an independent cohort of 119 AML patient 
samples analyzed using reduced representation bisulfite sequencing (56), which likewise identified 
hypermethylation in the ISYNA1 genic region in a subset of AML cases, which was absent in normal 
bone marrow cells (Figure S16). Taken together, these findings validate that aberrant hypermethylation 
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Discussion 
Our study identifies a myo-inositol auxotrophy as a previously unrecognized metabolic vulnerability in 
AML. We trace this auxotrophy to aberrant silencing of ISYNA1, which is the rate-limiting enzyme 
for myo-inositol biosynthesis. Our work suggests that normal cells maintain intra-cellular myo-inositol 
levels through the redundant mechanisms of de novo biosynthesis and SLC5A3-dependent transport 
from the extracellular microenvironment. Our work shows how ISYNA1 silencing eliminates this 
redundancy, which in turn drives an elevated demand for SLC5A3-dependent myo-inositol transport in 
AML (Figure 7F). 
 
The evolution of redundant mechanisms for sustaining intracellular myo-inositol is likely to reflect the 
vital function of this metabolite, which is well-supported by experiments in diverse eukaryotic species 
(57). Myo-inositol is incorporated as head group into a variety of lipids, which function to promote 
signal transduction in growth-promoting pathways (e.g. AKT-mTOR) (21). Hence, blockade of 
SLC5A3 in ISYNA1-deficient AML is likely to extinguish AKT-mTOR signaling, which would be 
expected to cause an acute arrest in cell proliferation. Targeting of SLC5A3 would also be expected to 
deplete the cell of inositol phosphates, which regulate calcium release as well as the function of 
chromatin remodeling complexes (57, 58). These myriad functions of myo-inositol for cell viability are 
likely to contribute to the fitness defects of targeting SLC5A3 in AML.  
 
Our study adds to a growing body of evidence highlighting how epigenetic silencing can alter 
metabolic pathways and lead to nutrient dependencies. Hypermethylation of the argininosuccinate 
synthetase (ASS1) gene promoter leads to an arginine dependency in several human cancers (8, 59, 60). 
Similarly, hypermethylation and silencing of asparagine synthetase (ASNS) has been linked to 
asparagine auxotrophy in lymphoid leukemia (6, 61, 62). Promoter hypermethylation of a rate-limiting 
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cholesterol biosynthetic enzyme, squalene mono-oxygenase (SQLE) leads to a cholesterol auxotrophy 
in anaplastic large cell lymphoma (9). It remains unclear as to why the CpG islands of metabolic genes 
are prone to DNA hyper-methylation, as it is unclear whether silencing of these genes confers a growth 
advantage in human cancer cells. Since epigenetic and metabolic regulation is tightly interconnected, it 
is possible that feedback regulation exists between the chromatin regulatory machinery and metabolite 
levels. For example, we observe that ISYNA1-silenced AML is correlated with the presence of 
IDH1/IDH2 gain-of-function mutations, which produce 2-hydroxyglutarate which in turn inhibits 
active DNA demethylation (63, 64). Thus, it is possible that the unique metabolic state of AML is the 
predisposing factor for ISYNA1 silencing as a passenger epigenetic event in this disease, a possibility 
that warrants additional investigation.  
 
The aberrant DNA methylation of ISYNA1 is unlikely to be unique to AML, as several other cancer 
types (e.g. breast invasion carcinoma) we surveyed in TCGA database also showed a similar pattern 
(Figure S17A-F). However, the correlation between SLC5A3 dependency and ISYNA1 expression is 
weak in non-AML cancer cell lines. This suggest that other factors might influence myo-inositol levels 
in non-AML contexts. Nevertheless, these findings raise the possibility that the SLC5A3 dependency 
and MI auxotrophy might be present more broadly across human cancers. 
 
Several mechanisms have been described by which the ISYNA1 gene is regulated in mammalian cells 
to control myo-inositol biosynthesis, which may predispose to gene silencing in AML. For example, 
the inositol hexakisphosphate kinase 1 (IP6K1) has been found in the nucleus where it acts directly to 
maintain transcription of ISYNA1 and prevent DNA hypermethylation (65). In addition, prior studies 
have shown that Musashi2, a known oncogene, regulates ISYNA1 expression in the context of cancer 
(66). The tumor suppressor p53 has also been shown to directly regulate the ISYNA1 promoter (67). 
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Our own genetic analysis of human samples suggests that mutations of the C/EBP transcription factor 
are associated with ISYNA1 hyper-methylation, which may influence the methylation state of this gene. 
Collectively, these studies suggest that several cancer-relevant pathways converge in regulating 
ISYNA1 expression, which might underlie the aberrant silencing of this gene in AML.  
 
Our work raises the possibility that the acquired dependency on SLC5A3 and extra-cellular myo-
inositol in AML might have therapeutic significance. In analogy to the use of asparaginase in 
lymphoblastic leukemias (68), one possibility for therapeutic intervention in ISYNA1-deficient AML 
would be to suppress plasma levels of myo-inositol using an infusion of catabolic enzymes. MIOX 
(myo-inositol oxygenase) is one such enzyme that oxidizes myo-inositol into D-glucuronic acid (69, 
70). Another enzyme capable of catabolizing myo-inositol is inositol dehydrogenase from Bacillus 
subsilis (71, 72). As an alternative strategy, several solute carriers have been targeted using small 
molecules (15). Thus, an attractive strategy would be to suppress SLC5A3 function. While Slc5a3-null 
mice die soon after birth due to respiratory failure from abnormal development of peripheral nerves, 
this phenotype can be rescued by prenatal myo-inositol supplementation. Adult Slc5a3-null mice show 
a decrease of tissue myo-inositol levels and reduced nerve conduction velocity, which can also be 
alleviated by myo-inositol supplementation (52). Taken together, our findings justify an investigation 
of myo-inositol lowering agents or SLC5A3 blockade as therapeutic interventions for the elimination 
of ISYNA1-deficient AML cells.  
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Material and Method 
 
Cell Lines and Culture 
All cell lines were authenticated using STR profiling. MOLM-13, MV-4-11, SEM, OCI-AML3, EOL-
1, U937, NOMO-1, HEL, SET-2, KASUMI-1 (human acute myeloid leukemia, AML), K562 (human 
chronic myeloid leukemia, CML), AsPC-1, MIA PaCa-2 (human pancreatic cancer) and NCI-H82 
(human small cell lung cancer, SCLC) cells were cultured in RPMI supplemented with 10% fetal 
bovine serum (FBS). MA9-ITD, MA9-RAS (engineered human AML) cells were cultured in IMDM 
supplemented with 20% FBS (73, 74). RH30, RD (human rhabdomyosarcoma), and HEK293T cells 
were cultured in DMEM supplemented with 10% FBS. NCI-H1048 (human SCLC) was cultured in 
DMEM:F12 supplemented with 0.005 mg/mL insulin, 0.01 mg/mL transferrin, 30 nM sodium selenite, 
10 nM hydrocortisone, 10 nM β-estradiol, 4.5 mM L-glutamine, and 5% FBS. Penicillin/streptomycin 
was added to all cell culture. All cell lines were cultured at 37˚C with 5% CO2, and were periodically 
tested negative for mycoplasma contamination. All experiments were performed within one month of 
thawing a cryopreserved vial of cells.  
 
To make myo-inositol deficient cell culture (-MI), customized RPMI medium without myo-inositol 
(Bio-Techne) was supplemented with dialyzed FBS (#26400044, ThermoFisher Scientific) and 
penicillin/streptomycin. The dialyzed FBS shows 100 times less myo-inositol level compared to 
regular FBS, validated by LC-MS. To measure cell growth in (-MI) cell medium as shown in Figure 4, 
cells were washed twice with PBS to remove residue cell medium, and then resuspended in (-MI) 
medium with one million cells per mL. One mL cells were transferred into one well in 12-well plates, 
with three replicates for each condition. Cell number and viability was measured using automated cell 
counter (Invitrogen Countess) every two days. For each passage, 0.4x10
6
 (for MOLM-13 cells) or 
0.2x10
6
 (for other lines) cells were passed on to the next passage. For MOLM-13, MV4-11, and U937 
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passage in MI-deficient medium. For these samples, 1/5 volume of the cells were passed to the next 
passage. We performed at least 2 biological replicates (each included 3 technical replicates) for each 
cell line tested. For (+MI) cell medium, 0.2 g/L (1.11 mM) myo-inositol (#I5125, Sigma) was added 







 Tg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ (known as NSGS) mice 





/SzJ (known as NSG) mice were used for validating individual gene knock-out in 
vivo. All animals were purchased from The Jackson Laboratory (jax.org). Animal procedures and 
studies were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at 
Cold Spring Harbor Laboratory. 
 
Plasmid Construction 
The lentiviral Cas9 vector (LentiV_Cas9_puro/Addgene #108100), the lentiviral sgRNA vectors 
(LRG2.1-GFP/Addgene #108098, LRG2.1-mCherry/Addgene #108099, the lentiviral luciferase vector 
(LentiV_Neo_Luc/Addgene #105621), and the lentiviral cDNA expression vector 
(LentiV_Neo/Addgene #108101) have been described in previous studies (42, 75). DNA oligos of the 
sgRNAs were cloned into LRG2.1-GFP/mCherry vectors using a BsmBI restriction site. The cDNAs 
of ISYNA1 (#OHu18552, GenScript) and SLC5A3 (#53836, Addgene) were cloned into LentiV_Neo 
vector using In-Fusion cloning system (Takara Bio), and flag tag was inserted to the C-terminus of the 
cDNAs. The same system was used to mutate the PAM sequences in the SLC5A3 gene. Dual targeting 
vectors were generated by inserting sgRNA1-scaffold-bU6-sgRNA2 sequence (synthesized as gene-
blocks by IDT) into the BsmBI site of LRG2.1-GFP-P2A-BlastR vector using Gibson Assembly 
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(NEB). The scaffold sequence for sgRNA1 was generated by replacing the stem-stem loop region of 
the LRG2.1 scaffold (76) with a previously described CRISPRi sgRNA scaffold (77). 
 
Construction of Domain-Focused sgRNA Library 
The Kinase sgRNA library and Transcription factor sgRNA library were described in the previous 
studies (39, 42). The other sgRNA libraries were generated in a similar fashion. The gene lists were 
obtained from HUGO Gene Nomenclature Committee database (HGNC, genenames.org). The domain-
focused sgRNA libraries were designed by using CSHL CRISPR sgRNA design tool (crispr.cshl.edu), 
and at least 6 sgRNAs were selected for each gene or domain. Non-targeting sgRNAs as negative 
control, and sgRNAs targeting essential genes as positive control, were added into the pooled sgRNA 
library. The pooled library was synthesized on an array platform (Twist Bioscience) and then cloned 
into the BsmBI restriction site of LRG2.1-GFP vector using Gibson Assembly System (NEB).  
 
Lentivirus Transduction 
Lentivirus was produced in HEK293T cells as described in the previous study (42). Briefly, 10 ug of 
plasmid DNA was mixed with helper plasmids (5 ug VSVG and 7.5 ug psPAX2) and 1 mg/mL 
polyethylenimine (PEI 25000). The mix was then used to transfect HEK293T cells in 10 cm dish. The 
mix was replaced by fresh cell media 6 hours post the transfection, and lentivirus-containing 
supernatant was collected at 24, 48, and 72 hours post-transfection. To infect cells with lentivirus, the 
target cells were mixed with the virus and 8 ug/mL polybrene in 12 well plates, and then centrifuged at 
1700 rpm for 45~60 min. Cell media was changed 24 hours post infection. For cells infected with 
LentiV_Neo or LentiV_Blast vector, G418 or Blasticidin was added to the cell culture at day 3 post 
infection, respectively. 
 
Pooled in vivo CRISPR Screening 
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Cas9 and Luciferase (Luc) expressing MOLM-13 cell line (MOLM-13-Cas9-Luc) was established by 
infecting MOLM-13 cells with LentiV_Cas9_puro and LentiV_Neo_Luc, and then selected with 
puromycin and G418. To improve in vivo engraftment efficiency, 5 million MOLM-13-Cas9-Luc cells 
were transplanted into two sub-lethally irradiated (2.5 Gy), 8-week-old female NSG mice through tail 
vein injection. The cells were collected from the bone marrow of the injected mice ten days post 
injection by flushing the tibia with phosphate buffered saline (PBS). The collected cells were then 
cultured in RPMI supplemented with 10% FBS, puromycin and G418 to remove murine cells. 
 
To determine virus titer for the sgRNA library, MOLM-13-Cas9-Luc cells were infected with different 
volumes of the virus using spin infection technique as described above. Flow cytometer (Guava 
easyCyte, Millipore) was used to determine the infection rate by measuring the percentage of GFP 
positive cells. The amount of virus that gave ~30% infection rate was used for further infection 
experiments. 
 
To ensure at least 1000 fold coverage of each sgRNA in the library, the amount of cells to be infected 
was calculated using the equation: cell number=sgRNA number/infection rate*1000. For instance, 
given the sgRNA number in the SLC sgRNA library was ~3000, and the infection rate was ~30%, at 
least 10 million cells were used for one CRISPR screening. Ten mice were planned to be injected, thus 
100 million cells were used for the initial infection. 
 
To perform in vivo CRISPR screening, the pre-engrafted MOLM-13-Cas9-Luc cells were infected with 
the library lentivirus. Three days post infection, the infection rate was checked by flow cytometer to 
ensure ~30% GFP positive cells. For the SLC sgRNA library, the infected wells were split into three 
groups. Group 1, ten million cells were spin-collected and kept frozen as P0. Group 2, ten million cells 
were kept growing in cell culture as in vitro CRISPR screening sample, in parallel of in vivo CRISPR 
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screening sample. During each passage, the percentage of GFP positive cells was measured, and the 
cell number was calculated using the equation above to ensure at least 1000 fold coverage of the 
sgRNA library. Group 3, one hundred million cells were collected, washed with PBS to remove any 
residual cell media, and then resuspended in 2 mL PBS (5X10
7
 cells/mL). 200 uL of the cells were 
transplanted to one sub-lethally irradiated (2.5 Gy), 8-week-old female NSGS mouse via tail vein 
injection. A total number of nine mice were successfully injected. The engraftment and growth of the 
injected human AML cells was monitored by biofluorescence imaging (IVIS Spectrum System, 
Caliper Life Sciences). Images were taken 10 minutes after intraperitoneal injection of D-luciferin (50 
mg/kg), every 3 days post injection. On day 12 post injection, the animals were euthanized. The spleen 
(SP) and bone marrow (BM) samples were collected. The spleen was broken down by gently crushing 
between the frost sides of two glass slides, and then filtered through a cell strainer. The bone marrow 
was flushed from tibia by injecting with PBS. Meanwhile, the in vitro samples were also spin-collected. 
The genomic DNA from P0, in vitro sample, individual SP and BM were purified using QIAamp DNA 
Mini kit (QIAGEN). The genomic DNA were then diluted into 100 ng/uL. An equal aliquot of 
genomic DNA from individual SP and BM were pooled to make pooled SP and pooled BM samples. 
The in vivo screening for other sgRNA libraries were performed in a similar fashion, with the amount 
of cells and the number of animals adjusted according to the sgRNA library size to ensure at least 
1000X coverage. 
 
Barcoded sequencing libraries for P0, in vitro, 9 individual SP, 9 individual BM, pooled SP, and 
pooled BM were prepared using the same method as described in the previous study (42). The libraries 
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The sequencing data was de-barcoded and subsequently mapped to the reference sgRNA library using 
a customized tool as described in the previous study (76). The screening data was analyzed using 
MAGeCK-MLE (78, 79). A beta score was calculated for each gene and negative control by the 
MAGeCK-MLE model. It is a measurement of gene selections similar to ‘log fold change’ in 
differential expression analysis (79). Negative beta score indicated negative selection, and positive beta 
score indicated positive selection. To calculate beta score for the non-targeting negative controls, every 
6 negative controls were pooled as a single target for the MAGeCK-MLE calculation. The data was 
visualized using Prism 8 program. 
 
Pooled in vitro CRISPR Screening 
Ten cell lines representing five different type of cancers were used for in vitro CRISPR screening of 
the SLC sgRNA library, including MOLM-13, HEL, NOMO-1 (AML), K562 (CML), AsPC-1, MIA 
PaCa-2 (pancreatic cancer), NCI-H82, NCI-H1048 (SCLC), RH30, RD (rhabdomyosarcoma). The 
Cas9 expressing cell lines were established by infecting with LentiV_Cas9_puro, and then selected 
with puromycin. The virus titer for each cell line was determined individually as described above. To 
ensure 1000 fold coverage of the library, at least 10 million cells were initially infected with the library 
with ~30% infection rate. Day 3 post infection, 10 million cells were collected and kept frozen as P0. 
Cells were passed every three days, cell number and GFP% were checked every passage. Cells 
collected at passage 5 and 8 were saved as P5 and P8 samples. Genomic DNA extraction, sequencing 
library preparation, and data analysis were performed the same way as described above. 
 
For the genome-wide CRISPR screens in Figure S13, Cas9 expressing MOLM13 and MOLM13
ISYNA1
 
cells were transduced with Human CRISPR Knockout Pooled Library (Brunello, Addgene #73178) 
with low MOI (~0.3). The original library vector contains puromycin selection marker, which was 
replaced with blasticidin-GFP selection marker. The transduced cells were selected with blasticidin, 
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and saved as P0. The cells were passaged for another 10 doublings, and saved as P10. Two biological 
replicates were performed. Sequencing of the sgRNAs was performed on NextSeq platform. Data 
analysis was performed the same way as described above. 
 
Competition-Based Cell Proliferation Assay 
Cas9 expressing cells were infected with sgRNA cloned into LRG2.1-GFP/mCherry, or dual-targeting 
vector. The percentage of GFP or mCherry positive cells was first measured at day 3 post infection (P0) 
by flow cytometer (Guava easyCyte, Millipore), and then measured every 2~3 days at each passage, 
till passage 5 or 6. The relative fluorescent% for each passage was calculated using the equation: 
relative fluorescent%=[fluorescent%]/[P0 fluorescent%] * 100%. Decrease of the fluorescent% 
indicated the infected (gene knock-out) cells were out-competed by the uninfected (wide type) cells.  
 
Cell cycle arrest analysis 
Cell cycle analysis as shown in Figure S7 was performed according to the manufacturer’s protocol 
(BD, FITC BrdU Flow Kit; Cat. No. 559619). Cells were pulsed with BrdU for 1 hour at 37 °C, and 
then were co-stained with 4’,6- diamidino-2-phenylindole (DAPI) for DNA content measurement. 
Cells were finally analyzed with a BD LSRFortessa flow cytometer (BD Biosciences) and FlowJo 
software (TreeStar). The experiments were performed in duplicates. 
 
Western Blot 
To detect the ISYNA1 expression levels in human AML cell lines, ten million cells were collected and 
cell pellet was resuspended in 500 uL 1X Laemli sample buffer (Bio-Rad). The cell lysate was then 
boiled for 10 min, separated by SDS-PAGE, followed by transfer to nitrocellulose membrane and 
immunoblotting with 1:500 diluted mouse monoclonal anti-ISYAN1(C-9) antibody (#sc-271830, Santa 
Cruz Biotechnology), and then with 1:10000 diluted polyclonal rabbit anti-mouse HRP antibody 
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(#P0260, Agilent Dako). For control, mouse monoclonal anti-HSC70 (B-6) antibody (#sc-7298, Santa 
Cruz Biotechnology) was used with 1:10000 dilution. 
 
To detect the recombinant ISYAN1-flag, ten million cells were collected two weeks post infection 
with cDNA vectors followed by G418 selection. Protein sample preparation and immunoblotting was 
the same as described above. For flag-tagged proteins, 1:5000 diluted mouse monoclonal anti-flag 
antibody (Sigma) was used, followed by a secondary antibody of rabbit anti-mouse HRP antibody 
(#P0260, Agilent Dako) with 1:10000 dilution. 
 
In vivo validation experiments 
For the in vivo validation as shown in Figure 3, pre-engraft MOLM-13-Cas9-Luc cells were infected 
with LRG2.1-sgROSA-GFP-BlastR or LRG2.1-sgSLC5A3-2-GFP-BlastR. At day 2 post infection, 
blasticidin was added to the cell culture to select for infected cells. After 3 days selection, the cells 
were collected, washed with PBS to remove residual media, and resuspended to 1X10
6
 cells/mL. 100 
uL cells were transplanted to one sub-lethally irradiated (2.5 Gy), 8-week-old female NSG mouse via 
tail vein injection. Five mice were injected for each sgRNA. AML development was monitored by 
biofluorescence imaging (IVIS Spectrum System, Caliper Life Sciences). Images were taken 10 
minutes after intraperitoneal injection of D-luciferin (50 mg/kg), on day 13, 16 and 19 post injection. 
 
For the in vivo validation as shown in Figure S8, pre-engraft MOLM-13-Cas9-Luc cells were infected 
with LRG2.1-sgROSA-GFP, LRG2.1-sgSLC5A3-1-GFP, LRG2.1-sgSLC5A3-2-GFP, LRG2.1-
sgCD47-1-GFP, or LRG2.1-sgCD47-2-GFP. Excessive lentivirus was used to ensure >90% infection 
rate. The cells were then transplanted to NSG mice as described above. 
 
Metabolomics analysis by liquid chromatography coupled to mass spectrometry (LC-MS)  
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For the LC-MS analysis shown in Figure 4, 0.5 million cells were infected with LRG2.1-sgROSA-
GFP-BlastR or LRG2.1-sgSLC5A3-2-GFP-BlastR in 12 well plates with 6 replicates. For the LC-MS 
analysis shown in Figure 6, MOLM13-Cas9 cells expressing EV or ISYNA1 were infected with 
LRG2.1-sgROSA-GFP-BlastR or LRG2.1-sgSLC5A3-2-GFP-BlastR in 12 well plates with 5 
replicates. The infected cells were selected with blasticidin at day 2 post infection, for 3 days. For the 
LC-MS analysis shown in Figure S11-C, HEL-Cas9 and K562-Cas9 cells were infected with indicated 
single or dual targeting sgRNA vectors with over 90% infection rate, in 12 well plates with 5 replicates, 
for 5 days. The cells were then collected for sample preparation. For the LC-MS analysis shown in 
Figure S11-D, HEL-Cas9 cells were infected with LRG2.1-sgROSA-GFP-BlastR or LRG2.1-
sgISYNA1-GFP-BlastR in 12 well plates with 5 replicates. The infected cells were selected with 
blasticidin at day 2 post infection for 7 days. At least 95% of GFP positive rate was achieved. The cells 
were then washed twice with PBS, and cultured in myo-inositol deficient medium (-MI) for another 4 
days before preparation for LC-MS. 
 
To prepare cells for LC-MS, cells were quickly washed in PBS before adding 1 mL of ice-cold 
extraction solution (50% methanol, 30% acetonitrile, 20% H2O) per four million cells. The cells were 
then scrapped and the suspension was snap frozen in liquid nitrogen. Samples were agitated using a 
Thermomixer (Eppendorf) at 1,400 rpm, 4°C for 15 min followed by incubation at -80°C for 1 h. 
Samples were then centrifuged at 15,000 rpm, 4°C for 10 min. The supernatants were further 
centrifuged for another 10 min. The supernatants were stored in autosampler vials at -80°C until 
analysis.  
 
Intracellular extracts from 5~6 independent cell cultures were analyzed for each condition. Samples 
were randomized in order to avoid bias due to machine drift and processed blindly. LC-MS analysis 
was performed using a Vanquish Horizon UHPLC system couple to a Q Exactive HF mass 
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spectrometer (both Thermo Fisher Scientific). Sample extracts (5 µL) were injected onto a Sequant 
ZIC-pHILC column (150 mm × 2.1 mm, 5 µm) and guard column (20 mm × 2.1 mm, 5 µm) from 
Merck Millipore kept at 45°C. The mobile phase was composed of 20 mM ammonium carbonate with 
0.1% ammonium hydroxide in water (solvent A), and acetonitrile (solvent B). The flow rate was set at 
200 μl/min with the previously described gradient (80). The mass spectrometer was operated in full 
MS and polarity switching mode. The acquired spectra were analyzed using XCalibur Qual Browser 
and XCalibur Quan Browser software (Thermo Fisher Scientific) by referencing to an internal library 
of compounds. 
 
Stable Isotope Tracing by LC-MS 
For tracing de novo myo-inositol synthesis from 
13
C labeled glucose as shown in Figure S14, 
13
C 
labeling medium was prepared by adding 
13
C labeled glucose (Sigma-Aldrich 389374) (final 
concentration 2000mg/L) and dialyzed FBS (final concentration 10%) to glucose free RPMI (Thermo 
Fisher Scientific 11879020). Cells were washed with PBS twice and seeded in 6-well plates with 
13
C 
labeling medium for 48 hours. Extracts from six independent cell cultures were analyzed for each 
condition. Briefly, after quick removal of the culture medium, cells were washed in PBS before adding 
extraction solution (50% methanol, 30% acetonitrile, 20% H2O). After centrifugation to remove the 
precipitated proteins and insoluble debris, the supernatants were collected and stored in autosampler 
vials at -80°C until analysis. Samples were randomized to avoid bias due to machine drift, and 
processed blindly. LC-MS analysis was performed using a Vanquish Horizon UHPLC system coupled 
to a Q Exactive HF mass spectrometer (both Thermo Fisher Scientific). Sample extracts were analyzed 
as previously described (80). The acquired spectra were analyzed using XCalibur Qual Browser and 
XCalibur Quan Browser software (Thermo Fisher Scientific) by referencing to an internal library of 
compounds. Metabolite peak areas were corrected for natural 
13
C abundance using the R package 
AccuCor (81). To calculate isotopologue distribution, corrected peak areas of each metabolite’s 
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isotopologues were normalized to the total metabolite pool (sum of all isotopologues of a given 
metabolite). Values of release of lactate were adjusted to cell density upon background subtraction. 
 
Nanopore sequencing  
crRNA guides specific to the regions of interest (ROI) were designed as per recommended guidelines 
described in the Nanopore infosheet on Targeted, amplification-free DNA sequencing using 
CRISPR/Cas (Version: ECI_S1014_v1_revA_11Dec2018). The crRNA sequences are provided in 
Supplementary Table 2. Guides were reconstituted to 100 μM using TE (pH 7.5) and pooled into an 
equimolar mix. For each distinct sample, four identical reactions were prepared parallelly using 5µg 
gDNA each. Ribonucleoprotein complex (RNPs) assembly, genomic DNA dephosphorylation, and 
Cas9 cleavage were performed as described in Gilpatrick et al. 2019 (82). Affinity-based Cas9-
Mediated Enrichment (ACME) using Invitrogen™ His-Tag Dynabeads™ was performed to pulldown 
Cas9 bound non-target DNA, increasing the proportion of on-target reads in the sample (83). The 
resultant product was cleaned up using 1X Ampure XP beads (Beckman Coulter, Cat #A63881), eluted 
in nuclease-free water, and pooled together. The ACME enriched sample was quantified using Qubit 
fluorometer (ThermoFisher Scientific) and carried forward to the adapter ligation step as described by 
Iyer et al (83). Sequencing adaptors from the Oxford Nanopore Ligation Sequencing Kit (ONT, SQK-
LSK109) were ligated to the target fragments using T4 DNA ligase (NEBNext Quick Ligation Module 
E6056). The sample was cleaned up using 0.3X Ampure XP beads (Beckman Coulter, Cat #A63881), 
washed with long-fragment buffer (LFB; ONT, SQK-LSK109), and eluted in 15 µl of elution buffer 
(EB; ONT, LSK109) for 30 min at room temperature. Resultant library was prepared for loading as 
described in the Cas9-mediated PCR-free enrichment protocol from ONT (Version: 
ENR_9084_v109_revH_04Dec2018) by adding 25 µL sequencing buffer (SQB; ONT, LSK109) and 
13 µl loading beads (LB; ONT, LSK109) to 12 µl of the eluate. Each sample was run on a FLO-
MIN106 R9.4.1 flow cell using the GridION sequencer.  
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Real time basecalling was performed with Guppy v3.2, and files were synced to our Isilon 400NL 
storage server for further processing on the shared CSHL HPCC. Nanopolish v0.13.2 (84) was used to 
call methylation per the recommended workflow.  Briefly, indexing was performed to match the ONT 
fastq read IDs with the raw signal level fast5 data. The ONT reads were then aligned to the human 
reference genome (UCSC hg38) using minimap2 v2.17 (85) and the resulting alignments were then 
sorted with samtools v0.1.19 (86). Nanopolish call-methylation was then used to detect methylated 
bases within the targeted regions – specifically 5-methylcytosine in a CpG context. The initial output 
file contained the position of the CpG dinucleotide in the reference genome and the methylation call in 
each read.  A positive value for log_lik_ratio was used to indicate support for methylation, using a 
cutoff value of 2.0. The helper script calculate_methylation.py was then used to calculate the 
frequency of methylation calls by genomic position. 
 
qPCR analysis of indel mutations 
To analyze sgRNA editing of genomic DNA as shown in Figure S5A, cells were infected with 
LRG2.1-sgROSA-GFP-BlastR, LRG2.1-sgSLC5A3-1-GFP-BlastR, or LRG2.1-sgSLC5A3-2-GFP-
BlastR. At day 2 post infection, blasticidin was added to the cell culture to select for infected cells. 
After 3 days selection, the cells were collected, and genomic DNA was extracted using QIAamp DNA 
Mini kit (QIAGEN). For qPCR, 20~25 ng of genomic DNA was used in each reaction with indicated 
primer set. The Ct value of non-sgRNA-target primer was used to normalize the data. To analyze 
SLC5A3 (r-1 and r-2) expression as shown in Figure S6E, MOLM-13 cells were infected with the 
indicated cDNA constructs, and were then selected with G418 for two weeks. Total RNA was 
extracted using TRIzol (ThermoFisher Scientific), and cDNA was synthesized using qScript cDNA 
SuperMix (Quanta). All qPCR experiments were performed using Power SYBR Green PCR Master 
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Mix (ThermoFisher Scientific) on a QuantStudio Flex Real-time PCR machine (ThermoFisher 
Scientific).  
 
AML patient data  
TCGA PanCancer AML patient data, including gene expression and mutation, were downloaded via 
cBioPortal (cbioportal.org) (87, 88, 89). The same patients’ DNA methylation data was downloaded 
via NCI Genomic Data Commons (gdc.cancer.gov) (55). The Glass et al data from AML (n=119) and 
normal (n=22) individuals were downloaded from GEO (accession number GSE98350) (56). After 
filtering and normalizing by coverage, a methylBase object containing the methylation information and 
locations of cytosines that were present in at least 5 samples per condition (meth.min=5) was generated 
using MethylKit (version 1.9.3) and R statistical software (version 3.5.1). Percent methylation for each 
CG for each donor, was calculated using the MethylKit ‘percMethylation’ function. Bedtools  intersect 
function was used to determine overlap with CpGi from hg19.  
 
ChIP-seq data analysis 
For ChIP-seq analysis shown in Figure S15-A, raw reads were obtained from public GEO datasets,  
MOLM13 (GSE63782/ GSM1652920), K562 (GSE63782/GSM1652918) (90), MV411 (GSE79899/ 
GSM2108039), THP-1(GSE79899/ GSM2108046) (91), HEL (GSE109492/ GSM2944364) (42), and 
mapped to the human genome (hg19) using Bowtie2 software with sensitive settings (92). Duplicate 
reads were removed prior to peak calling using MACS2 software using 5% FDR cut off and broad 
peak option (93). Sequencing depth normalized ChIP-seq pileup tracks were visualization using the 
IGV genome browser (94). 
 
Statistics  
Error bars represent the mean plus or minus standard error of the mean, and n refers to the number of 
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biological repeats. Statistical significance was evaluated by p value using GraphPad Prism software or 
Scipy package from Python 3.8.5 as indicated in the figure legends. For Kaplan-Meier survival curves, 
the log rank (Mantel-Cox) test was used to estimate median overall survival and statistical significance. 
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FIGURE LEGENDS 
Figure 1. A domain-focused CRISPR screening method for identifying in vivo-relevant AML 
dependencies. (A) Overview of in vivo genetic screening procedure using domain-focused sgRNA 
libraries. GPCR, G-protein coupled receptor; NGS, Next Gen Sequencing. The numbers represent the 
number of genes in each sgRNA library. Figures for mouse bone marrow, spleen and NGS were 
created with a licensed version of BioRender . (B-E) Examples of in vivo CRISPR screening results 
with sgRNA libraries targeting kinases (B), transcription factors (C), chromatin regulators (D), and 
membrane proteins (E). The gene beta score was calculated using MAGeCK (78, 79). The beta score 
describes how the gene knockout alters cell fitness: a positive beta score indicates positive selection, 
and a negative beta score indicates negative selection. The screening results using pooled spleen 
samples were compared with in vitro screening results. Core fitness genes (95) are labeled in red, 
negative control sgRNAs are labeled in blue. (F) Venn diagram comparing genetic dependencies 
identified by in vivo screening with in vitro screening. The in vivo-relevant targets were determined 
using spleen data with p-value <0.05, FDR <0.25, beta score <0. For in vivo- and in vitro-specific 
targets, the absolute value of differential beta scores were shown as pie charts. Genes with a 
differential beta score of 2 or greater are listed. 
 
Figure 2. Dependency on SLC5A3 is in vivo-relevant and AML-specific. (A) Analysis of Project 
Achilles genetic screening data, evaluating the leukemia-biased essentiality of 239 in vivo-relevant 
dependencies. The in vivo screening dependencies were determined by p-value <0.05, FDR <0.25, beta 
score <0. The average gene effect scores were calculated using Achilles Gene Effect 20Q3 data. The p 
values compared gene effect scores in leukemia vs. other cancers using an unpaired Student’s t-test. (B)  
Comparison of dependencies of top SLC candidates between leukemia and other type of cancers. The 
dependency of SLC5A3 is the most leukemia-biased among the candidates. Data is obtained from 
DepMap database (20Q3). Plotted as average gene effect score with standard deviation in leukemia 
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cell lines vs. non-leukemia cell lines. The p values were calculated using unpaired Student’s t-test. (* 
p-value <0.05) (C) Summary of in vivo vs in vitro CRISPR screening results of the SLC sgRNA library. 
 
Figure 3. Validation of SLC5A3 dependency. (A) Summary of in vitro validation experiments of 
individual sgRNAs (linked to GFP) in competition-based proliferation assays in AML cell lines. 
Plotted is the log2 transformed fold change of GFP positive cell percentage at day 18 vs. day 3 post the 
infection of sgRNA lentivirus. Shown as mean with standard deviation of 2~7 biological replicates. (B) 
Procedure of in vivo validation of SLC5A3 dependency in human AML. MOLM-13 cells expressing 
Cas9 and Luciferase were transduced with sgROSA or sgSLC5A3-2 (linked to GFP/bsr), and then 
selected with Blasticidin. The SLC5A3 knock-out cells (sgSLC5A3) and control cells (sgROSA) were 
then transplanted into NSG mice via tail vein injection. (C) Bioluminescence imaging of NSG mice 
transplanted with MOLM-13 cells transduced with the indicated sgRNA. The images were taken on 
day 13, 16, and 19 post-transplantation. (D) Quantification of bioluminescence from (C). Values 
represent total flux as photons per second (Mean  Standard Deviation). The p-value was calculated 
using unpaired Student’s t test (n=5). (E) Survival curves of mice shown in (C). The p-value was 
calculated using Log-rank (Mantel-Cox) test (n=5). 
 
Figure 4. SLC5A3-dependent AML lines are myo-inositol auxotrophs. (A) Liquid Chromatography 
Mass Spectrometry (LC-MS) analysis of cellular myo-inositol and glutamine levels in MOLM-13 and 
MV4-11 cells transduced with indicated sgRNA. The p-value was calculated using unpaired Student’s 
t test (n=6). (**** p<0.0001). (B-C) Depletion of myo-inositol in the cell culture medium affects the 
growth of SLC5A3-dependent lines MOLM-13, MV4-11, and U937 (B), but not SLC5A3-independent 
lines HEL, K562, and SET-2 (C). A customized RPMI cell culture medium without myo-inositol, 
supplied with dialyzed FBS, was used (-MI). Additional myo-inositol supplement (1.11 mM/0.2 g/L) 
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was added into the medium for rescue (+MI). (Shown as mean with standard deviation of 2-4 
biological replicates. The p values were calculated using 2way ANOVA Sidak test to compare each 
line graph). (D) Competition-based proliferation assays in MOLM13 and MV4-11 cells transduced 
with indicated sgRNA, and treated with additional myo-inositol supplement. The base level of myo-
inositol in RPMI medium is 0.035 g/L (0.19 mM). To rescue the phenotype, additional myo-inositol 
was added to the cell culture to make myo-inositol concentration as 0.07 g/L (0.38 mM) and 0.175 g/L 
(0.95 mM). Myo-inositol from FBS (100% FBS contains ~0.9 mM, determined by LC-MS, 10% FBS 
was added to cell culture medium) was not included. (Shown as mean with standard deviation of 3 
replicates with independent infections). 
 
Figure 5. Transcriptional silencing of ISYNA1 leads to SLC5A3 dependency through a synthetic 
lethal genetic interaction. (A) Summary of two major sources of cellular myo-inositol: transported 
from extracellular environment by SLC5A3; de novo biosynthesis from glucose. The rate limiting de-
novo myo-inositol biosynthesis enzyme is inositol-3-phosphate synthase 1, encoded by the ISYNA1 
gene. (B) SLC5A3 dependency in AML (and K562) cell lines correlates with ISYNA1 expression. 
Data from DepMap database (Achilles 20Q3). (C) Expression of ISYNA1 in AML (and K562) cell 
lines. The ISYNA1 gene mRNA expression data was obtained from Cancer Cell Line Encyclopedia 
(CCLE) database (96, 97). The ISYNA1 protein expression in AML lines and K562 (CML) was 
detected by Western blot, shown as one of two replicates. (D) A double knock-out construct that co-
targets two genes by two sgRNAs driven by human U6 (hU6) or bovine U6 (bU6) promoter, 
respectively. The sgRNAs are linked to GFP. (E) Competition-based proliferation assays in Cas9 
expressing SLC5A3-independent cell lines, following infection with indicated co-targeting sgRNA 
constructs. Double knock-out both ISYNA1 and SLC5A3 leads to growth phenotype (red). (Shown as 
mean with standard deviation of 3 replicates of independent infections.). (F) Western blot shows the 
depletion of ISYNA1 protein in HEL and K562 cells following infection with indicated sgRNA. (G) 
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Competition-based proliferation assays in Cas9 expressing HEL and K562 cells following infection 
with indicated sgRNA. The experiment was performed in myo-inositol deficient RPMI medium 
without myo-inositol supplement (-MI, blue), or with 0.05 g/L (0.28 mM) myo-inositol supplement 
(+MI, red). (Shown as mean with standard deviation of 3 replicates with independent infections.) 
 
Figure 6. Re-expression of ISYNA1 eliminates SLC5A3 dependency and the myo-inositol 
auxotrophy. (A) Western blot shows overexpression of flag-tagged ISYNA1 in indicated AML cell 
lines. (B) Competition-based proliferation assays in SLC5A3-dependent AML lines expressing EV 
(empty vector, blue) or ISYNA1(red), following infection with indicated sgRNA linked to GFP. 
(Shown as mean with standard deviation of 3 replicates from independent infections). (C) LC-MS 
analysis in MOLM-13 cells expressing EV or ISYNA1, following infection with indicated sgRNA. 
The p-value was calculated using 2way ANOVA (n=5). (** p=0.0011, **** p<0.0001). (D) 
Overexpression of ISYNA1 in MOLM-13 cells rescues the growth defect in myo-inositol deficient 
medium (-MI), but has no impact on the cell growth in medium with myo-inositol supplement (+MI). 
(Shown as mean with standard deviation of two biological replicates, each includes 3 replicates with 
independent infection. The p value was calculated using 2way ANOVA Sidak test.) 
  
Figure 7. The ISYNA1 gene is epigenetically silenced by aberrant DNA methylation in a subset of 
AML. (A-B) CpG methylation status at the ISYNA1 gene locus in AML cell lines (MOLM-13, MV4-
11, HEL), normal hematopoietic stem and progenitor cell (HSPC) (A), and AML patients (B). The 
AML cell line methylation was measured by Nanopore sequencing. The HSPC methylation was 
measured by genome-wide bisulfite sequencing, obtained from a previous study (54). The AML 
patients’ data was obtained from TCGA PanCancer AML database (55). The TCGA AML patients’ 
data used DNA methylation array with reduced CpG representation, shown as ‘TCGA CpG’ (blue 
dots). The CpGs at ISYNA1 promoter (dark blue dots in TCGA CpG) show hypermethylated in 
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SLC5A3-dependent/ISYNA1-low AML lines MOLM-13 and MV4-11, but hypomethylated in 
SLC5A3-independent/ISYNA1-high HEL line as well as normal HSPC cells. These regions were also 
shown aberrantly methylated in a subset of AML patients (B). (C) ISYNA1 gene expression level is 
significantly lower in high methylation group, compared to low methylation group (p=0.02). The high- 
and low-groups were determined by the Z scores of average DNA methylation levels of the three 
promoter CpGs (TCGA) described above (Figure S15E). (D) CEBPA, IDH1, and IDH2 mutations are 
enriched in the high ISYNA1 methylation group, while DNMT3A mutation is enriched in low 
methylation group. Data was obtained from TCGA PanCancer AML database via cBioportal. (E) AML 
patients with IDH2 mutations show lower ISYNA1 gene expression (p=0.03). Data was obtained from 
TCGA PanCancer AML database via cBioportal. (F) A model depicting synthetic lethality between 
SLC5A3 and ISYNA1 in AML.  
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